321e06bd-31c9-416d-88a0-4c400286f89e
Forskolin-induced Swelling in Intestinal OrganoidsFunctional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumorsDrug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancerA Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityLong-Term Survival of Transplanted Autologous Canine Liver Organoids in a COMMD1-Deficient Dog Model of Metabolic Liver DiseaseRectal Organoids Enable Personalized Treatment of Cystic FibrosisEstablishment of patient-derived cancer organoids for drug-screening applicationsLipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cellsApplication of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinomaA living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacologyLong-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoidsNext-Generation Surrogate Wnts Support Organoid Growth and Deconvolute Frizzled Pleiotropy In VivoForskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutationsMedium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived OrganoidsOngoing chromosomal instability and karyotype evolution in human colorectal cancer organoidsStratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
externalOrganisations
02bab4842c814977b3d29f1e49e9b898172f69005a5343158093e7e3346ad09d1ef18f635f0b40c3b25bc06414737d012074bbaf6465462ba8253dc3b6a5ce4d2bc4555fac28437a868a48bbbbd60f1d3aa7895a13ee411b94f1a1bad2198c753cbd721eaa594b2d9cdb3cfc3aef908d4623e601b9694f00836000592aefd56a4673215f68ff47c6a860f538ead82e8c4da435d401bb4464a92881d9b20433cf62b613876f27480c9e4ec361f1f28d6563d3a4f67b1f45b197929c10736f866963fc3a7be1c94de48eb99c9008c42e987adbfe7b524b4c2ab73c10abe6072af47e4ba857158a48429e556a4a581801af7e678f0a0e3b4189b218dde925d2e59f959bb46aaea447e5967ea88f460619bb98762af6294a432d95e17b5f7950b0ab9c957072bdae4dd2b4a14e529436c66c9ea79e5bf15548dbb36375826e851936a0bd0994c948475e969680de2e21ba41b0f8f29e895742859e77b372f7f37ef1bde8860ddd954decbaf8efb30e7d1e2dc889db02d0e54c69b1668f2a96eed75cccd884b3463c4f1fa919f43190c90f16d04355edc9694841a9f0da0daf354ecfd5090c21bc21443d98d5cff72e6217cdd8c5cf3c21924a6fa9fac538984182afe331dc12c1e5444896e3934b87de0864e54f060f53fb4794a61f44da414d7379ee7dddee45e746549039baabb21e474df0e348dac47a4f2cbbfc232d211c138af19328cdbc8c4c3188082c079d535b6f